Target Name: OLFML1
NCBI ID: G283298
Review Report on OLFML1 Target / Biomarker Content of Review Report on OLFML1 Target / Biomarker
OLFML1
Other Name(s): Olfactomedin-like protein 1 (isoform a) | OLFL1_HUMAN | Olfactomedin-like protein 1 | Olfactomedin-Like 1 | Olfactomedin like 1, transcript variant 1 | OLFML1 variant 1 | MVAL564 | olfactomedin like 1 | UNQ564

OLFML1: A Potential Drug Target and Biomarker for Neurological Disorders

Olfactomedin-like protein 1 (OLFML1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and kidneys. It is a member of the Olfactomedin gene family, which is known for the involvement of cathecholamines , such as angiotensin II, in various physiological processes.

OLFML1 was first identified in the brain as a potential drug target due to its known role in the regulation of angiotensin II signaling. Angiotensin II is a potent stimulator of the sympathetic-adrenal response, and has been implicated in a number of neurological and cardiovascular disorders , including hypertension, heart failure, and neurodegenerative diseases.

To further investigate the potential role of OLFML1 as a drug target, researchers have used a variety of techniques to study its function in both in vitro and in vivo settings. One study published in the journal NeuroImage used a technique called immunofluorescence to visualize OLFML1 expression in the brain and its localization to the cell surface. The results showed that OLFML1 was expressed in the brain and its localization to the cell surface was consistent with its known role in the regulation of angiotensin II signaling.

Another study published in the journal Molecular Psychiatry used a technique called RNA interference to knockdown the expression of OLFML1 in rats and then evaluated the impact on their behavior and physiological processes. The results showed that OLFML1 knockdown significantly reduced the expression of OLFML1 and improved the behavior of the rats, suggesting that OLFML1 may play a role in the regulation of behavioral processes.

OLFML1 has also been investigated as a potential biomarker for various neurological and cardiovascular disorders. A study published in the journal Neuropharmacology used a technique called ELISA to measure the level of OLFML1 in brain tissue from mice with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease . The results showed that the level of OLFML1 in the brain tissue was significantly decreased in mice with these disorders compared to age-matched control mice.

Another study published in the journal PLoS One used a technique called qRT-PCR to investigate the expression of OLFML1 in patient samples from a neurodegenerative disease database. The results showed that OLFML1 was expressed in the brain tissue from patients with various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In conclusion, OLFML1 is a protein that has been identified as a potential drug target due to its known role in the regulation of angiotensin II signaling and its potential as a biomarker for various neurological and cardiovascular disorders. Further research is needed to fully understand the role of OLFML1 in these processes and to explore its potential as a therapeutic agent.

Protein Name: Olfactomedin Like 1

The "OLFML1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OLFML1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2